MLAB Biosciences Welcomes Dr. Edward M. Kaye as New Scientific Advisory Board Chair

MLAB Biosciences Appoints Dr. Edward M. Kaye as Chair of Scientific Advisory Board

On September 15, 2025, MLAB Biosciences, a pioneering biotechnological firm focused on developing innovative therapies for neuromuscular diseases, announced a significant addition to its team. Dr. Edward M. Kaye, M.D., former CEO of both Sarepta Therapeutics and Stoke Therapeutics, has been appointed as the Chair of the Scientific Advisory Board (SAB) for MLAB. This strategic move is set to enhance MLAB's objective of establishing a world-class advisory board at a pivotal moment in the company's growth.

Dr. Kaye is renowned in the biopharmaceutical industry, particularly in the field of Duchenne muscular dystrophy (DMD) treatment development. His leadership at Sarepta was instrumental in the approval of Exondys 51, heralded as the first therapy to modify the disease's progression. This positioned Sarepta as a key player in the neuromuscular medical field, underscoring Dr. Kaye’s influence and expertise in advancing treatments for muscular disorders.

Sean Cao, the current CEO and Co-Founder of MLAB Biosciences, expressed enthusiasm regarding Dr. Kaye's involvement, describing it as a clear endorsement of MLAB's scientific methodologies. Drawing from his extensive experience in DMD and neuromuscular drug development, Dr. Kaye will provide substantial guidance as MLAB accelerates its innovative therapies into clinical settings.

In his declaration, Dr. Kaye acknowledged the distinctive focus of MLAB on muscle regeneration via the Notch signaling pathway. He conveyed optimism about the potential of this novel strategy not only to address DMD but also to serve as a foundational therapy benefitting a wide range of patients with related conditions. His dedication to supporting MLAB’s mission of delivering transformative therapies is evident as he joins this ambitious team.

MLAB’s lead therapeutic initiative, MLAB-001, is a specialized antibody-fusion protein aimed at activating the Notch pathway to promote muscle regeneration. Importantly, this approach does not rely solely on dystrophin—specifically targeting mutations—allowing MLAB-001 to provide potential benefits across the entire DMD patient spectrum. This positions MLAB as a forward-thinking entity in the biopharmaceutical landscape, particularly with its innovative approaches combining existing treatment modalities.

The appointment of Dr. Kaye marks the first in what is expected to be a series of distinguished appointments within MLAB's Scientific Advisory Board. The ongoing effort to assemble an authoritative team of neuromuscular experts suggests that MLAB is committed to establishing itself at the forefront of therapy development for neuromuscular diseases. This comprehensive strategy, underpinned by expert guidance and groundbreaking research, is central to their mission of providing enhanced therapeutic solutions.

About MLAB Biosciences

MLAB Biosciences operates under the umbrella of ABio-X Holding, focusing on promoting advancements in protein therapeutics targeting musculoskeletal disorders. Through innovative science and transformative technology convergence, ABio-X endeavors to redefine the future of patient care worldwide. Backed by CBC Group, an asset management firm specializing in healthcare and based in Singapore, MLAB seeks to push the boundaries of what is feasible in neuromuscular medicine, ultimately translating research breakthroughs into accessible, life-altering treatments for patients everywhere.